Suven Life Sciences Limited has reported a utilization of Rs 85,764.02 Lakh for the quarter ending September 30, 2025, following its recent preferential issue of convertible warrants. This report was submitted to both the Bombay Stock Exchange and the National Stock Exchange on November 12, 2025, as part of compliance with the Securities and Exchange Board of India regulations. The funds for the issue were raised between June 21 and June 30, 2025, with 25% of the total amount received during the quarter, which amounts to Rs 21,441.00 Lakh. The remaining 75%, totaling Rs 64,323.01 Lakh, is expected to be received as warrant holders exercise their options within the next 18 months.

The Monitoring Agency Report issued by Crisil Ratings Limited confirmed that there were no deviations from the intended utilization of the proceeds as per the offer document. The agency, while not conducting an audit, stated that the information provided was believed to be accurate and reliable. The report did not reveal any significant discrepancies and asserted that all funds were used in accordance with the disclosures made to shareholders. Notably, Rs 9,232.42 Lakh of the remaining amount has already been received, assuring stakeholders of the company's compliance with its financial commitments.

Suven Life Sciences, operating in the pharmaceuticals sector, is led by promoters Venkateswarlu Jasti and Sudharani Jasti. The successful execution of the preferential issue reflects the company's robust financial strategy and commitment to transparency. As the company progresses, it will maintain ongoing communication with investors and adhere to regulatory requirements to ensure confidence in its operations and future endeavors.